Robin Filshie

3.3k total citations · 1 hit paper
41 papers, 1.5k citations indexed

About

Robin Filshie is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Robin Filshie has authored 41 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 25 papers in Hematology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Robin Filshie's work include Chronic Lymphocytic Leukemia Research (21 papers), Chronic Myeloid Leukemia Treatments (17 papers) and Eosinophilic Disorders and Syndromes (8 papers). Robin Filshie is often cited by papers focused on Chronic Lymphocytic Leukemia Research (21 papers), Chronic Myeloid Leukemia Treatments (17 papers) and Eosinophilic Disorders and Syndromes (8 papers). Robin Filshie collaborates with scholars based in Australia, United States and New Zealand. Robin Filshie's co-authors include Andrew Grigg, Timothy P. Hughes, Susan Branford, Anthony K. Mills, Anthony P. Schwarer, Christopher Arthur, John F. Seymour, David M. Ross, Cassandra Slader and Deborah L. White and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Robin Filshie

39 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Peers

Countries citing papers authored by Robin Filshie

Since Specialization

Citations

This map shows the geographic impact of Robin Filshie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Filshie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Filshie more than expected).

Fields of papers citing papers by Robin Filshie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Filshie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Filshie. The network helps show where Robin Filshie may publish in the future.

Co-authorship network of co-authors of Robin Filshie

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Filshie. A scholar is included among the top collaborators of Robin Filshie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Filshie. Robin Filshie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study 2024 ·Blood Advances ·Emma Verner, Amanda Johnston, (unknown), Eliza A. Hawkes, (unknown), Tara Cochrane, Chan Y. Cheah, Robin Filshie, Duncan Purtill, Hanlon Sia, Anoop Enjeti, Christina Brown, Nick Murphy, Jennifer Curnow, Kenneth Lee, Maher K. Gandhi, Mannu Walia, Belinda Butcher, Judith Trotman	1
2	Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL 2023 ·Hematological Oncology ·Emma Verner, Anna Johnston, (unknown), Eliza A. Hawkes, (unknown), Tara Cochrane, Chan Y. Cheah, Robin Filshie, Duncan Purtill, Hanlon Sia, Anoop Enjeti, Christina Brown, Nick Murphy, Jennifer Curnow, (unknown), Maher K. Gandhi, Belinda Butcher, Judith Trotman	1
3	Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report 2022 ·Journal of Ophthalmic Inflammation and Infection ·(unknown), Michael Ng, (unknown), Robin Filshie, Richard Stawell, Roderick O’Day	2
4	Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study 2021 ·Blood ·Emma Verner, Amanda Johnston, (unknown), Eliza A. Hawkes, (unknown), Tara Cochrane, (unknown), Robin Filshie, Duncan Purtill, Hanlon Sia, Anoop Enjeti, Christina Brown, (unknown), Jennifer Curnow, Kenneth Lee, Mannu Walia, Belinda Butcher, Judith Trotman	5
5	Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome 2021 ·Blood ·Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne-Marie Watson, (unknown), Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Leah J. Hogdal, Ying Zhou, David Hoffman, (unknown), Guillermo Garcia‐Manero	13
6	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy 2020 ·Leukemia & lymphoma ·(unknown), (unknown), (unknown), Gareth P. Gregory, Constantine S. Tam, Hang Quach, (unknown), Robin Filshie, Matthew Ku, (unknown), Jake Shortt, Stephen Opat	8
7	Lymphoma, a great imitator in neurology 2020 ·Journal of Clinical Neuroscience ·Wei Zhen Yeh, (unknown), Penny McKelvie, Steven Collins, (unknown), Robin Filshie, Tom Sutherland, Nicholas Trost, Katrina Reardon	2
8	The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia 2019 ·Leukemia & lymphoma ·Masa Lasica, Abbey Willcox, Kate Burbury, David M. Ross, Susan Branford, Jason Butler, Robin Filshie, Henry Januszewicz, David Joske, Anthony K. Mills, David Simpson, Constantine S. Tam, Kerry Taylor, Anne-Marie Watson, Max Wolf, Andrew Grigg	15
9	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells 2018 ·Leukemia ·(unknown), David M. Ross, Ilaria S. Pagani, Naranie Shanmuganathan, Chung Hoow Kok, John F. Seymour, Anthony K. Mills, Robin Filshie, Christopher Arthur, Phuong Dang, Verity A Saunders, Jodi Braley, Agnes S. M. Yong, David T Yeung, Deborah L. White, Andrew Grigg, Anthony P. Schwarer, Susan Branford, Timothy P. Hughes	56
10	Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone 2017 ·BMJ Case Reports ·Kate Robson, Danielle Clucas, Robin Filshie, Harshal Nandurkar	6
11	Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia 2015 ·International Journal of Hematology ·(unknown), David T Yeung, Robin Filshie, Timothy P. Hughes, Harshal Nandurkar	5
12	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation 2014 ·Leukemia ·(unknown), Linda W. Horton, Loïc Ysebaert, M Levade, Kate Burbury, Seng‐Lai Tan, M. Cole‐Sinclair, John Reynolds, Robin Filshie, (unknown), Amit Khot, Shahneen Sandhu, Michael J. Keating, Harshal Nandurkar, Constantine S. Tam	169
13	An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial 2014 ·Leukemia & lymphoma ·Jason D. Lickliter, Kerry Taylor, Jeff Szer, Andrew Grigg, Christopher Arthur, Timothy P. Hughes, Simon Durrant, Robin Filshie, (unknown), Michael Seldon, (unknown), Andy Boyd, James D’Rozario, Kim Rooney, Kevin Lynch, Ken Bradstock, (unknown)	0
14	Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR 2010 ·Leukemia ·David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, (unknown), Cassandra Slader, Catherine J. Field, P Dang, Robin Filshie, Anthony K. Mills, Andrew Grigg, J V Melo, Timothy P. Hughes	194
15	High incidence ofPneumocystis jiroveciipneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone 2010 ·Leukemia & lymphoma ·Sarah Kamel, (unknown), (unknown), Robin Filshie, Harshal Nandurkar, Constantine S. Tam	52
16	Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near‐complete cytogenetic response to interferon‐α 2007 ·Cancer ·Susan Branford, Timothy P. Hughes, Alvin Milner, Rachel Koelmeyer, Anthony P. Schwarer, Chris Arthur, Robin Filshie, (unknown), Kevin Lynch, Kerry Taylor	7
17	Delayed‐onset neutropenia associated with rituximab therapy 2003 ·British Journal of Haematology ·(unknown), (unknown), Andrew Grigg, Robin Filshie, Frank Firkin	102
18	Cytokines in Haemopoietic Progenitor Mobilisation for Peripheral Blood Stem Cell Transplantation 2002 ·Current Pharmaceutical Design ·Robin Filshie	14
19	Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy. 2001 ·Blood ·Amy K. Keating, Robin Filshie, Peter Mollee, (unknown)	1
20	VLA‐4 is involved in the engraftment of the human pre‐B acute lymphoblastic leukaemia cell line NALM‐6 in SCID mice 1998 ·British Journal of Haematology ·Robin Filshie, David Gottlieb, Kenneth F. Bradstock	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact